Clinical trials sponsored by Sichuan Baili Pharmaceutical Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by Sichuan Baili Pharmaceutical Co., Ltd.

• A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
  NCT07502300 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
  NCT07642024 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
  NCT05262491 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 12 locations
• A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
  NCT05470348 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
  NCT06437509 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
  NCT07518173 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
  NCT06830889 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
  NCT06891833 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 30 locations
• A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
  NCT07264816 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
  NCT06114511 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
  NCT07178795 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
  NCT06505824 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
  NCT06500052 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
  NCT07232420 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
  NCT06857227 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
  NCT06857214 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
  NCT06609187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
  NCT06612840 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
  NCT07274852 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
  NCT06008054 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Sichuan Baili Pharmaceutical Co., Ltd. recruiting for?

Sichuan Baili Pharmaceutical Co., Ltd. is the lead sponsor of 20 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.